Skewed lung CCR4 to CCR6 CD4+ t cell ratio in Idiopathic Pulmonary Fibrosis is associated with pulmonary function

Frontiers in Immunology

Volumn 7, Issue NOV, 2016, Pages

  Adegunsoye, Ayodeji ^a   Hrusch, Cara L ^a   Bonham, Catherine A ^a   Jaffery, Mohammad R ^a   Blaine, Kelly M ^a   Sullivan, Meghan ^a   Churpek, Matthew M ^a   Strek, Mary E ^a   Noth, Imre ^a   Sperling, Anne I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CD4; Chemokine receptors; Idiopathic pulmonary fibrosis; Lung function; T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FUNCTION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VITAL CAPACITY;

EID: 85006154616     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00516     Document Type: Article

References (55)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 183:788-824. doi:10.1164/rccm.2009-040GL
2. Khalil W, Xia H, Bodempudi V, Kahm J, Hergert P, Smith K, et al. Pathologic regulation of collagen I by an aberrant protein phosphatase 2A/histone deacetylase C4/microRNA-29 signal axis in idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol (2015) 53:391-9. doi:10.1165/rcmb.2014-0150OC
3. Maher TM, Evans IC, Bottoms SE, Mercer PF, Thorley AJ, Nicholson AG, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 182:73-82. doi:10.1164/rccm.200905-0674OC
4. Li Y, Jiang D, Liang J, Meltzer EB, Gray A, Miura R, et al. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med (2011) 208:1459-71. doi:10.1084/jem.20102510
5. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol (2009) 86:1111-8. doi:10.1189/jlb.0309132
6. Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol (2008) 40:2129-40. doi:10.1016/j.biocel.2008.02.012
7. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 179:588-94. doi:10.1164/rccm.200810-1534OC
8. Xu YD, Hua J, Mui A, O'Connor R, Grotendorst G, Khalil N. Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2003) 285:L527-39. doi:10.1152/ajplung.00298.2002
9. Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J (2003) 22:69-76. doi:10.1183/09031936.03.00014703
10. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 370:2071-82. doi:10.1056/NEJMoa1402584
11. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 370:2083-92. doi:10.1056/NEJMoa1402582
12. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res (2014) 15:157. doi:10.1186/s12931-014-0157-3
13. Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol (1999) 65:187-95.
14. Christensen PJ, Goodman RE, Pastoriza L, Moore B, Toews GB. Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent. Am J Pathol (1999) 155:1773-9. doi:10.1016/S0002-9440(10)65493-4
15. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med (2013) 5:205ra136. doi:10.1126/scitranslmed.3005964
16. Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, Montgomery R, et al. Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am J Respir Crit Care Med (2013) 187:180-8. doi:10.1164/rccm.201206-1109OC
17. Moore BB, Moore TA. Viruses in idiopathic pulmonary fibrosis. Etiology and Exacerbation. Ann Am Thorac Soc (2015) 12(Suppl 2):S186-92. doi:10.1513/AnnalsATS.201502-088AW
18. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol (2007) 179:2592-9. doi:10.4049/jimmunol.179.4.2592
19. Idiopathic Pulmonary Fibrosis Clinical Research NetworkRaghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 366:1968-77. doi:10.1056/NEJMoa1113354
20. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med (2010) 207:535-52. doi:10.1084/jem.20092121
21. Boveda-Ruiz D, D'Alessandro-Gabazza CN, Toda M, Takagi T, Naito M, Matsushima Y, et al. Differential role of regulatory T cells in early and late stages of pulmonary fibrosis. Immunobiology (2013) 218:245-54. doi:10.1016/j.imbio.2012.05.020
22. Simonian PL, Wehrmann F, Roark CL, Born WK, O'Brien RL, Fontenot AP. Gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med (2010) 207:2239-53. doi:10.1084/jem.20100061
23. Keane MP, Belperio JA, Burdick MD, Strieter RM. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2001) 281(1):L92-7.
24. Saito A, Okazaki H, Sugawara I, Yamamoto K, Takizawa H. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol (2003) 132:168-76. doi:10.1159/000073718
25. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 4:583-94. doi:10.1038/nri1412
26. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med (2012) 18:1028-40. doi:10.1038/nm.2807
27. Moore BB, Fry C, Zhou Y, Murray S, Han MK, Martinez FJ, et al. Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. Front Med (Lausanne) (2014) 1:56. doi:10.3389/fmed.2014.00056
28. Garibaldi BT, D'Alessio FR, Mock JR, Files DC, Chau E, Eto Y, et al. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment. Am J Respir Cell Mol Biol (2013) 48:35-43. doi:10.1165/rcmb.2012-0198OC
29. Kolahian S, Fernandez IE, Eickelberg O, Hartl D. Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol (2016) 55(3):309-22. doi:10.1165/rcmb.2016-0121TR
30. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One (2010) 5:e8959. doi:10.1371/journal.pone.0008959
31. Braun A, Worbs T, Moschovakis GL, Halle S, Hoffmann K, Bolter J, et al. Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration. Nat Immunol (2011) 12:879-87. doi:10.1038/ni.2085
32. Iwami D, Brinkman CC, Bromberg JS. Vascular endothelial growth factor c/vascular endothelial growth factor receptor 3 signaling regulates chemokine gradients and lymphocyte migration from tissues to lymphatics. Transplantation (2015) 99:668-77. doi:10.1097/TP.0000000000000561
33. Becattini S, Latorre D, Mele F, Foglierini M, De Gregorio C, Cassotta A, et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science (2015) 347:400-6. doi:10.1126/science.1260668
34. Wells AU, Behr J, Costabel U, Cottin V, Poletti V. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J (2012) 39:805-6. doi:10.1183/09031936.00009112
35. Ely KH, Cauley LS, Roberts AD, Brennan JW, Cookenham T, Woodland DL. Nonspecific recruitment of memory CD8+ T cells to the lung airways during respiratory virus infections. J Immunol (2003) 170:1423-9. doi:10.4049/jimmunol.170.3.1423
36. Kohlmeier JE, Miller SC, Smith J, Lu B, Gerard C, Cookenham T, et al. The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity (2008) 29:101-13. doi:10.1016/j.immuni.2008.05.011
37. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy (2011) 3:1223-33. doi:10.2217/imt.11.100
38. Haring JS, Badovinac VP, Harty JT. Inflaming the CD8+ T cell response. Immunity (2006) 25:19-29. doi:10.1016/j.immuni.2006.07.001
39. Chen G, Shankar P, Lange C, Valdez H, Skolnik PR, Wu L, et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood (2001) 98:156-64. doi:10.1182/blood.V98.1.156
40. Galati D, De Martino M, Trotta A, Rea G, Bruzzese D, Cicchitto G, et al. Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pulmonary fibrosis patients. Cytokine (2014) 66:119-26. doi:10.1016/j.cyto.2013.12.003
41. Shimizu Y, Dobashi K, Endou K, Ono A, Yanagitani N, Utsugi M, et al. Decreased interstitial FOXP3(+) lymphocytes in usual interstitial pneumonia with discrepancy of CXCL12/CXCR4 axis. Int J Immunopathol Pharmacol (2010) 23:449-61. doi:10.1177/039463201002300207
42. Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P, et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 179:1121-30. doi:10.1164/rccm.200812-1936OC
43. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today (1998) 19:568-74. doi:10.1016/S0167-5699(98)01346-2
44. Allavena P, Luini W, Bonecchi R, D'Amico G, Bianchi G, Longoni D, et al. Chemokines and chemokine receptors in the regulation of dendritic cell trafficking. Chem Immunol (1999) 72:69-85. doi:10.1159/000058727
45. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 374:222-8. doi:10.1016/S0140-6736(09)60551-1
46. Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol (2013) 13:607-14. doi:10.1038/nri3476
47. Chen F, Liu Z, Wu W, Rozo C, Bowdridge S, Millman A, et al. An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. Nat Med (2012) 18:260-6. doi:10.1038/nm.2628
48. Mora AL, Woods CR, Garcia A, Xu J, Rojas M, Speck SH, et al. Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol (2005) 289:L711-21. doi:10.1152/ajplung.00007.2005
49. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol (1999) 162:2347-52.
50. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE Jr. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest (2008) 133:226-32. doi:10.1378/chest.07-1948
51. Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol (2000) 164:6406-16. doi:10.4049/jimmunol.164.12.6406
52. Pignatti P, Brunetti G, Moretto D, Yacoub MR, Fiori M, Balbi B, et al. Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am J Respir Crit Care Med (2006) 173:310-7. doi:10.1164/rccm.200502-244OC
53. Nibbering PH, van der Heide A, van Furth R. Macrophages in bronchoalveolar lavage fluid are not representative of macrophages in granulomas of the lungs of BCG-infected mice. J Pathol (1989) 157:253-61. doi:10.1002/path.1711570313
54. Paradis IL, Dauber JH, Rabin BS. Lymphocyte phenotypes in bronchoalveolar lavage and lung tissue in sarcoidosis and idiopathic pulmonary fibrosis. Am Rev Respir Dis (1986) 133:855-60.
55. Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J (2015) 46:1740-50. doi:10.1183/13993003.01558-2014